Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluating RELiZORB Use for the Treatment of Feeding Intolerance in Adults With Moderate to Severe Acute Pancreatitis
Sponsor: Northwell Health
Summary
The goal of this study is to learn if Relizorb, a fat-digesting enzyme, can improve tolerance of tube feeds in adult patients with moderate to severe pancreatitis. The main question it aims to answer is: Does Relizorb allow more nutrition to be delivered to participants than they received without it? Participants will be observed with standard, universal monitoring after adding Relizorb to their nutrition regimen.
Official title: Open-label, Multicenter, Phase IV, Study Evaluating RELiZORB Use for the Treatment of Feeding Intolerance in Adults With Moderate to Severe Acute Pancreatitis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2025-12-08
Completion Date
2026-12
Last Updated
2026-05-13
Healthy Volunteers
No
Interventions
RELiZORB digestive enzyme (immobilized lipase) cartridge
An in-line digestive enzyme cartridge designed for hydrolyzing lipids within enteral nutrition will be used to improve tube feed tolerance in patients with moderate to severe pancreatitis.
Locations (5)
South Shore University Hospital
Bay Shore, New York, United States
North Shore University Hospital
Manhasset, New York, United States
Lenox Hill Hospital
Manhattan, New York, United States
Long Island Jewish Medical Center
New Hyde Park, New York, United States
Staten Island University Hospital
Staten Island, New York, United States